Universal Beteiligungs und Servicegesellschaft mbH Buys New Shares in Veracyte, Inc. (NASDAQ:VCYT)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 176,518 shares of the biotechnology company's stock, valued at approximately $6,990,000. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.23% of Veracyte as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Veracyte during the 4th quarter valued at about $64,000. Palisades Investment Partners LLC bought a new stake in shares of Veracyte during the 4th quarter valued at about $6,487,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Veracyte by 20.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,463 shares of the biotechnology company's stock valued at $6,909,000 after buying an additional 30,059 shares during the last quarter. Vident Advisory LLC bought a new stake in shares of Veracyte during the 4th quarter valued at about $364,000. Finally, State of Wyoming grew its position in shares of Veracyte by 237.5% during the 4th quarter. State of Wyoming now owns 9,682 shares of the biotechnology company's stock valued at $383,000 after buying an additional 6,813 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen cut shares of Veracyte from a "buy" rating to a "hold" rating in a research report on Friday. Craig Hallum assumed coverage on shares of Veracyte in a research report on Thursday, March 20th. They issued a "buy" rating and a $45.00 target price for the company. Needham & Company LLC decreased their target price on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Stephens restated an "overweight" rating and issued a $45.00 target price on shares of Veracyte in a research report on Wednesday, March 26th. Finally, UBS Group decreased their target price on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $40.90.

Veracyte Price Performance

Shares of Veracyte stock traded down $0.20 on Tuesday, hitting $26.54. The company had a trading volume of 451,715 shares, compared to its average volume of 898,927. The business has a 50-day simple moving average of $29.87 and a 200-day simple moving average of $36.26. The company has a market cap of $2.08 billion, a PE ratio of -177.08 and a beta of 2.14. Veracyte, Inc. has a 52 week low of $19.73 and a 52 week high of $47.32.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.